<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03761784</url>
  </required_header>
  <id_info>
    <org_study_id>SGT-65-04</org_study_id>
    <nct_id>NCT03761784</nct_id>
  </id_info>
  <brief_title>A Study of S6G5T-3 in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sol-Gel Technologies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sol-Gel Technologies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12
      weeks in Patients with acne vulgaris
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase 3, double blind, vehicle-controlled study, patients will be admitted into this
      multi-center, double blind, randomized, vehicle controlled, parallel group pivotal study only
      after a written informed consent has been obtained and after all inclusion/exclusion criteria
      have been met. Male and female patients at least 9 years of age with facial acne vulgaris
      will be eligible for enrollment for daily treatment with S6G5T-3 or its vehicle S6G5T-8, for
      12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Actual">December 17, 2019</completion_date>
  <primary_completion_date type="Actual">December 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of patients with the primary measure of success &quot;Clear&quot; (0) or &quot;Almost clear&quot; (1) in the IGA relative to Baseline at Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion Counts</measure>
    <time_frame>Week 12</time_frame>
    <description>Absolute change from Baseline for inflammatory and non-inflammatory lesion count on the face at Week 12</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">424</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>S6G5T-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-3</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-8</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must sign an Institutional Review Board (IRB) approved written informed
             consent for this study.

          2. Male and female 9 years of age and older.

          3. Have two (2) or fewer cysts or nodules

        Exclusion Criteria:

          1. More than two acne nodules or cysts (defined as an inflammatory lesion greater than or
             equal to 5 mm in diameter).

          2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.)

          3. History of blood dyscrasia (e.g., leukemia, haemophilia, sickle cell anemia, multiple
             myeloma, etc.)

          4. Underlying disease that requires the use of interfering topical or systemic therapy.

          5. Other dermatological conditions that require the use of interfering topical or
             systemic therapy or that might interfere with study assessments such as, but not
             limited to, atopic dermatitis, perioral dermatitis, or rosacea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

